CDT Quote, Financials, Valuation and Earnings

Liminatus Pharma has a net margin of -- compared to CDT Equity, Inc.'s net margin of --. CDT Equity, Inc.'s return on equity of -- beat Liminatus Pharma's return on equity of --.

CDT Equity, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Liminatus Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that CDT Equity, Inc. has higher upside potential than Liminatus Pharma, analysts believe CDT Equity, Inc. is more attractive than Liminatus Pharma.

CDT Equity, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Liminatus Pharma has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

CDT Equity, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Liminatus Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CDT Equity, Inc. pays -- of its earnings as a dividend. Liminatus Pharma pays out -- of its earnings as a dividend.

CDT Equity, Inc. quarterly revenues are --, which are larger than Liminatus Pharma quarterly revenues of --. CDT Equity, Inc.'s net income of -$7.1M is higher than Liminatus Pharma's net income of --. Notably, CDT Equity, Inc.'s price-to-earnings ratio is -- while Liminatus Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CDT Equity, Inc. is -- versus -- for Liminatus Pharma. Usually stocks with elevated PS ratios are considered overvalued.

Maze Therapeutics, Inc. has a net margin of -- compared to CDT Equity, Inc.'s net margin of --. CDT Equity, Inc.'s return on equity of -- beat Maze Therapeutics, Inc.'s return on equity of -35.16%.

CDT Equity, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Maze Therapeutics, Inc. has an analysts' consensus of $46.56 which suggests that it could grow by 10.64%. Given that Maze Therapeutics, Inc. has higher upside potential than CDT Equity, Inc., analysts believe Maze Therapeutics, Inc. is more attractive than CDT Equity, Inc..

CDT Equity, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Maze Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

CDT Equity, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Maze Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CDT Equity, Inc. pays -- of its earnings as a dividend. Maze Therapeutics, Inc. pays out -- of its earnings as a dividend.

CDT Equity, Inc. quarterly revenues are --, which are smaller than Maze Therapeutics, Inc. quarterly revenues of --. CDT Equity, Inc.'s net income of -$7.1M is higher than Maze Therapeutics, Inc.'s net income of -$30.1M. Notably, CDT Equity, Inc.'s price-to-earnings ratio is -- while Maze Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CDT Equity, Inc. is -- versus 501.13x for Maze Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Oruka Therapeutics, Inc. has a net margin of -- compared to CDT Equity, Inc.'s net margin of --. CDT Equity, Inc.'s return on equity of -- beat Oruka Therapeutics, Inc.'s return on equity of -25.76%.

CDT Equity, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Oruka Therapeutics, Inc. has an analysts' consensus of $49.45 which suggests that it could grow by 53.97%. Given that Oruka Therapeutics, Inc. has higher upside potential than CDT Equity, Inc., analysts believe Oruka Therapeutics, Inc. is more attractive than CDT Equity, Inc..

CDT Equity, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oruka Therapeutics, Inc. has a beta of -0.409, suggesting its less volatile than the S&P 500 by 140.861%.

CDT Equity, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oruka Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $19.36 per share. CDT Equity, Inc. pays -- of its earnings as a dividend. Oruka Therapeutics, Inc. pays out -- of its earnings as a dividend.

CDT Equity, Inc. quarterly revenues are --, which are smaller than Oruka Therapeutics, Inc. quarterly revenues of --. CDT Equity, Inc.'s net income of -$7.1M is higher than Oruka Therapeutics, Inc.'s net income of -$30.3M. Notably, CDT Equity, Inc.'s price-to-earnings ratio is -- while Oruka Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CDT Equity, Inc. is -- versus -- for Oruka Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.